Evidence map›Paper›PMID 41210517›Full record

ArticleO&G open2025

Hysterectomy Status and Outcomes in Patients With Grade 1, Stage IA Endometrioid Adenocarcinoma.

Vasanti Jhaveri, Larissa Meyer, Lu Chen, Koji Matsuo, Roshni P Romero, Victor Khor, Yvonne G Lin, Jason D Wright, Sarah P Huepenbecker

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in O&G open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Vasanti JhaveriDivision of Gynecologic Oncology, St. Luke's University Health Network, Bethlehem, Pennsylvania; the Division of Gynecologic Oncology, MD Anderson Cancer Center, Houston, Texas; Genentech, A Member of the Roche Group, South San Francisco, and the Division of Gynecologic Oncology, University of Southern California, Los Angeles, California; and the Division of Gynecologic Oncology, Columbia University, New York, New York.
Larissa MeyerDivision of Gynecologic Oncology, St. Luke's University Health Network, Bethlehem, Pennsylvania; the Division of Gynecologic Oncology, MD Anderson Cancer Center, Houston, Texas; Genentech, A Member of the Roche Group, South San Francisco, and the Division of Gynecologic Oncology, University of Southern California, Los Angeles, California; and the Division of Gynecologic Oncology, Columbia University, New York, New York.
Lu ChenDivision of Gynecologic Oncology, St. Luke's University Health Network, Bethlehem, Pennsylvania; the Division of Gynecologic Oncology, MD Anderson Cancer Center, Houston, Texas; Genentech, A Member of the Roche Group, South San Francisco, and the Division of Gynecologic Oncology, University of Southern California, Los Angeles, California; and the Division of Gynecologic Oncology, Columbia University, New York, New York.
Koji MatsuoDivision of Gynecologic Oncology, St. Luke's University Health Network, Bethlehem, Pennsylvania; the Division of Gynecologic Oncology, MD Anderson Cancer Center, Houston, Texas; Genentech, A Member of the Roche Group, South San Francisco, and the Division of Gynecologic Oncology, University of Southern California, Los Angeles, California; and the Division of Gynecologic Oncology, Columbia University, New York, New York.
Roshni P RomeroDivision of Gynecologic Oncology, St. Luke's University Health Network, Bethlehem, Pennsylvania; the Division of Gynecologic Oncology, MD Anderson Cancer Center, Houston, Texas; Genentech, A Member of the Roche Group, South San Francisco, and the Division of Gynecologic Oncology, University of Southern California, Los Angeles, California; and the Division of Gynecologic Oncology, Columbia University, New York, New York.
Victor KhorDivision of Gynecologic Oncology, St. Luke's University Health Network, Bethlehem, Pennsylvania; the Division of Gynecologic Oncology, MD Anderson Cancer Center, Houston, Texas; Genentech, A Member of the Roche Group, South San Francisco, and the Division of Gynecologic Oncology, University of Southern California, Los Angeles, California; and the Division of Gynecologic Oncology, Columbia University, New York, New York.
Yvonne G LinDivision of Gynecologic Oncology, St. Luke's University Health Network, Bethlehem, Pennsylvania; the Division of Gynecologic Oncology, MD Anderson Cancer Center, Houston, Texas; Genentech, A Member of the Roche Group, South San Francisco, and the Division of Gynecologic Oncology, University of Southern California, Los Angeles, California; and the Division of Gynecologic Oncology, Columbia University, New York, New York.
Jason D WrightDivision of Gynecologic Oncology, St. Luke's University Health Network, Bethlehem, Pennsylvania; the Division of Gynecologic Oncology, MD Anderson Cancer Center, Houston, Texas; Genentech, A Member of the Roche Group, South San Francisco, and the Division of Gynecologic Oncology, University of Southern California, Los Angeles, California; and the Division of Gynecologic Oncology, Columbia University, New York, New York.
Sarah P HuepenbeckerDivision of Gynecologic Oncology, St. Luke's University Health Network, Bethlehem, Pennsylvania; the Division of Gynecologic Oncology, MD Anderson Cancer Center, Houston, Texas; Genentech, A Member of the Roche Group, South San Francisco, and the Division of Gynecologic Oncology, University of Southern California, Los Angeles, California; and the Division of Gynecologic Oncology, Columbia University, New York, New York.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo compare clinicodemographic factors and outcomes of patients with grade 1, stage IA endometrioid adenocarcinoma who did and did not undergo hysterectomy.

methodsThis is a retrospective cohort study using data from the SEER (Surveillance, Epidemiology and End Results) registry program, which collates population-based cancer registry information from 26.5% of the U.S. population. The SEER database identified patients aged 18 years or older with grade 1, stage IA endometroid adenocarcinoma from 2010 to 2020. The primary outcome was prevalence of patients who did and did not undergo hysterectomy. Secondary outcomes included endometrial and cardiovascular-specific death and all-cause mortality by surgical status and age. Descriptive and comparative statistics between the hysterectomy and nonhysterectomy cohorts were completed. Survival between surgical cohorts was compared using Fine-Gray models for cause-specific death (endometrial cancer, cardiovascular) and Cox models for all-cause mortality.

resultsOf 27,331 patients, 26,984 (98.7%) had hysterectomy and 347 (1.3%) did not. Most patients were between age 50 and 69 years (67.2%) and were non-Hispanic White (66.9%). Patients without hysterectomy were more likely to be younger than age 50 (54.8% vs 16.8%,

conclusionPatients from racial and ethnic minority groups and with extremes of age were less likely to undergo hysterectomy. Deaths resulting from endometrial cancer and cardiovascular disease and all-cause mortality were higher in patients who did not undergo hysterectomy.

Identifiers

PMID41210517
PMCPMC12591699

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.